103 studies found for:    Melanoma (women OR woman OR female)
Hide Display Options

Display Options

Study Details
Participant Details
Rank Status Study
1 Completed Illness Related Distress in Women With Clinically Localized Cutaneous Melanoma
Condition: Melanoma
Intervention: Behavioral: questionnaire on-line or if uncomfortable with a computer interface, paper copies will be provided
2 Completed Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass
Conditions: Breast Cancer;   Genitourinary Cancer;   Malignant Female Reproductive System Neoplasm;   Melanoma;   Sarcoma
Intervention: Procedure: Punch Biopsy
3 Recruiting Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Ipilimumab;   Other: Quality-of-Life Assessment;   Biological: Recombinant Interferon Alfa-2b
4 Recruiting Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Bevacizumab;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis
5 Recruiting Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye
Conditions: Recurrent Uveal Melanoma;   Stage IIIA Uveal Melanoma;   Stage IIIB Uveal Melanoma;   Stage IIIC Uveal Melanoma;   Stage IV Uveal Melanoma
Interventions: Drug: Cabozantinib S-malate;   Drug: Dacarbazine;   Other: Laboratory Biomarker Analysis;   Drug: Temozolomide
6 Recruiting Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
Condition: Melanoma (Skin)
Interventions: Drug: dasatinib;   Other: laboratory biomarker analysis
7 Recruiting Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Drug: Dabrafenib;   Other: Laboratory Biomarker Analysis;   Drug: Trametinib
8 Completed Vaccine Therapy in Treating Patients With Metastatic Cancer
Conditions: Lung Cancer;   Adult Soft Tissue Sarcoma;   Colorectal Cancer;   Bone Cancer;   Ovarian Sarcoma;   Melanoma;   Colon Cancer;   Rectal Cancer;   Breast Cancer;   Eye Cancer;   Uterine Sarcoma
Interventions: Drug: interleukin-2;   Drug: MAGE-12 peptide vaccine;   Drug: Montanide ISA-51
9 Completed Microarray Analysis for Human Genetic Disease
Conditions: Breast Neoplasm;   Hereditary Neoplastic Syndrome;   Melanoma;   Ovarian Neoplasm
10 Completed
Has Results
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Conditions: Melanoma;   Metastases
Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody;   Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine
11 Active, not recruiting The Incidence of Breast and Other Cancers Among Female Flight Attendants
Conditions: Thyroid Cancer;   Breast Cancer;   Non-Melanoma Skin Cancer;   Melanoma
12 Recruiting Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma
Condition: Metastatic Melanoma
Intervention: Radiation: WBRT
13 Recruiting Neurotropic Melanoma of the Head and Neck
Condition: Melanoma
Interventions: Other: Observation;   Radiation: Radiation Therapy
14 Completed SWOG-9430: Surgery in Treating Patients With Metastatic Melanoma
Condition: Melanoma (Skin)
Intervention: Procedure: Surgery
15 Recruiting A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma
Conditions: Advanced Melanoma;   Metastatic Melanoma
16 Active, not recruiting
Has Results
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage III Melanoma;   Stage IV Melanoma
Interventions: Biological: ipilimumab;   Biological: sargramostim
17 Terminated Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma
Condition: Melanoma
18 Recruiting A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
Condition: Melanoma
Interventions: Biological: Poly-ICLC;   Biological: Peptides
19 Completed A Follow-up Study of Women Evaluated and Treated for Infertility
Conditions: Ovarian Cancer;   Breast Cancer;   Endometrial Cancer;   Thyroid Cancer;   Colrectal Cancer, Melanoma
20 Completed Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Condition: Melanoma (Skin)
Interventions: Genetic: comparative genomic hybridization;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Other: immunohistochemistry staining method

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years